Bachelor of Science
Date of Graduation
Preeclampsia is a disease that results in pathologies in both the mother and the fetus that lead to oxidative stress. A decrease in vascular endothelial growth factor (VEGF) signaling may be one factor that contributes to this pathology. We hypothesize that by increasing vascular endothelial growth factor receptor 2 (VEGFR2) expression via administration of L-tyrosine phosphate (LTP) nanoparticles, the conditions of both the mother and fetus will be improved. Following treatment with the nanoparticles, we will employ a lucigenin chemiluminescence assay to determine levels of oxidative stress within the placenta. There are three groups that will be compared which are the control group and two experimental groups. The control group is the SHAM, one experimental group is the reduced uterine perfusion pressure (RUPP), a common model for preeclampsia, and the other experimental group is the RUPP treated with the nanoparticle. Once finished, we hypothesize that placental samples from VEGFR2-treated RUPP animals will display less oxidative stress than untreated RUPP animals, similar to that seen from SHAM controls. These studies will indicate whether RUPP pathology is associated with placental oxidative stress, and identify potential therapeutic roles for VEGFR2 nanoparticles.
Rolando J. Ramirez
Jordan M. Renna
Kaser, Madison, "Effect of Altered VEGFR2 Expression on Oxidative Stress in a Rodent Model of Preeclampsia Pathology" (2016). Williams Honors College, Honors Research Projects. 409.